• Explore /
  • Poster
  • / ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.

ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.

Abstract Poster

Authors

Domenica Lorusso

Domenica Lorusso

Fondazione IRCCS, Foundation Policlinico Universitario Agostino Gemelli IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

Domenica Lorusso , Nicoletta Colombo , Robert L. Coleman , Leslie M. Randall , Linda R. Duska , Yang Xiang , Kosei Hasegawa , Angelica Nogueira Rodrigues , David Cibula , Mansoor Raza Mirza , Benoit You , Ana Oaknin , Melissa Christiaens , Cagatay Taskiran , Elena Ioana Braicu , Jacob Korach , Christian Marth , Stephen Michael Keefe , Martina Puglisi , Sandro Pignata

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Clinical Trial Registration Number

NCT04221945

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS6096)

DOI

10.1200/JCO.2020.38.15_suppl.TPS6096

Abstract #

TPS6096

Poster Bd #

267

Abstract Disclosures

Similar Posters

First Author: Robert L. Ferris

First Author: Ronnie Shapira-Frommer

First Author: Bradley J. Monk

Poster

2017 ASCO Annual Meeting

A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.

A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.

First Author: Linda R. Duska